<DOC>
	<DOCNO>NCT01097317</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , carboplatin vinorelbine , work different way stop growth tumor cell , either kill cell stop dividing . Chemotherapy lead loss leg muscle strength . Neuromuscular electrical stimulation may improve muscle strength quality life . It yet know whether chemotherapy give together neuromuscular electrical stimulation effective chemotherapy alone treat patient non-small cell lung cancer . PURPOSE : This randomized phase II trial study first-line chemotherapy give together neuromuscular electrical stimulation see well work compare chemotherapy alone treat patient non-small cell lung cancer .</brief_summary>
	<brief_title>First-Line Chemotherapy With Without Neuromuscular Electrical Stimulation Treating Patients With Non-Small Cell Lung Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - To determine feasibility first-line palliative chemotherapy alone versus palliative chemotherapy combination neuromuscular electrical stimulation ( NMES ) patient non-small cell lung cancer . Secondary - To determine NMES safe patient undergo palliative chemotherapy . - To determine extent 3 4 course palliative chemotherapy impact leg muscle strength , body composition , physical activity level use NMES influence change . - To determine rate recovery decline leg muscle strength , body composition , physical activity level follow completion 3 4 course palliative chemotherapy use NMES influence change . - To assess patient attitude use NMES palliative chemotherapy . OUTLINE : Patients randomize 1 2 treatment arm . - Arm I ( control ) : Patients receive first-line palliative chemotherapy comprise carboplatin vinorelbine week 1 , 4 , 7 , 10 part usual care Nottingham University Hospital National Health Service Trust . - Arm II ( experimental ) : Patients receive chemotherapy arm I . Patients also undergo , home , neuromuscular electrical stimulation ( NMES ) week 2-12 ( anterior thigh ) 3 time week 30 minute . NMES treatment increase duration weekly basis 11 % 18 % 25 % , remain constant thereafter . All patient undergo assessment quadriceps muscle strength , body composition , physical activity level , nutritional intake , fatigue baseline week 9 , week 17 20 . Patients complete quality-of-life questionnaire ( EORTC-C30 LC-13 ) baseline , week 9 , week 17 20 . After completion study treatment , patient follow 8 week .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Fatigue</mesh_term>
	<mesh_term>Vinorelbine</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm nonsmall cell lung cancer Scheduled receive 3 4 course firstline palliative chemotherapy PATIENT CHARACTERISTICS : ECOG performance status 02 Life expectancy &gt; 3 month Not pregnant nursing Able use neuromuscular electrical stimulation device No implant cardiac pacemaker No epilepsy No spinal cord pathology PRIOR CONCURRENT THERAPY : See Disease Characteristics</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2010</verification_date>
	<keyword>chemotherapeutic agent toxicity</keyword>
	<keyword>musculoskeletal complication</keyword>
	<keyword>fatigue</keyword>
	<keyword>stage I non-small cell lung cancer</keyword>
	<keyword>stage II non-small cell lung cancer</keyword>
	<keyword>stage IIIA non-small cell lung cancer</keyword>
	<keyword>stage IIIB non-small cell lung cancer</keyword>
	<keyword>stage IV non-small cell lung cancer</keyword>
	<keyword>recurrent non-small cell lung cancer</keyword>
</DOC>